Literature DB >> 1576503

Proliferation indices of invasive breast carcinomas after in vivo 5-bromo-2'-deoxyuridine labelling: a flow cytometric study of 75 tumours.

D A Rew1, I D Campbell, I Taylor, G D Wilson.   

Abstract

In vivo labelling of human breast tumours with 5-bromo-2'-deoxyuridine and analysis of proliferation by multiparameter flow cytometry is a new tool by which the labelling index, S phase duration (TS) and potential doubling time (Tpot) of the tumour can be estimated. Tumour specimens from 75 patients with invasive breast carcinoma were studied. Six tumours could not be analysed, and the TS and Tpot values could not be calculated for a further 18. The median labelling index (n = 69) was 4.2 per cent. The median TS (n = 51) was 8.7 h and the median Tpot (n = 51) was 8.2 days. The median intra-assay coefficient of variation for determination of the labelling index was 0.29 in five tumours. There were no significant differences in the total labelling index, TS or Tpot when patients were stratified according to lymph node status, tumour size, tumour grade or menopausal status.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1576503     DOI: 10.1002/bjs.1800790418

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  9 in total

Review 1.  Continuous infusion of chemotherapy: focus on 5-fluorouracil and fluorodeoxyuridine.

Authors:  R L Poorter; P J Bakker; C H Veenhof
Journal:  Pharm World Sci       Date:  1998-04

Review 2.  Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part II: Oncology, chemotherapy and carcinogenesis.

Authors:  F Dolbeare
Journal:  Histochem J       Date:  1995-12

3.  Growth rate of lung metastases and S-phase fraction as determined by flow cytometry from the primary tumour in 25 patients with bone or soft-tissue sarcomas.

Authors:  C Blomqvist; R Huuhtanen; Y Pan; T Wiklund; M Tarkkanen; M Virolainen; B Tribukait
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

4.  Iododeoxyuridine labelling of S-phase fraction in fine needle aspirates from breast carcinomas.

Authors:  R A Maas; P F Bruning; A J Breedijk; J L Peterse
Journal:  J Clin Pathol       Date:  1996-07       Impact factor: 3.411

5.  Potential tumour doubling time: determination of Tpot for various canine and feline tumours.

Authors:  U Schwyn; N E Crompton; H Blattmann; B Hauser; B Klink; A Parvis; D Ruslander; B Kaser-Hotz
Journal:  Vet Res Commun       Date:  1998-06       Impact factor: 2.459

6.  4-Hydroxytamoxifen, an active metabolite of tamoxifen, does not alter the radiation sensitivity of MCF-7 breast carcinoma cells irradiated in vitro.

Authors:  J N Sarkaria; E M Miller; C J Parker; V C Jordan; R T Mulcahy
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

7.  Mathematical optimization of the combination of radiation and differentiation therapies for cancer.

Authors:  Jeff W N Bachman; Thomas Hillen
Journal:  Front Oncol       Date:  2013-03-18       Impact factor: 6.244

8.  Intra-tumoral heterogeneity of tumour potential doubling times (Tpot) in colorectal cancer.

Authors:  M S Wilson; C M West; G D Wilson; S A Roberts; R D James; P F Schofield
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

9.  An assessment of the reliability and reproducibility of measurement of potential doubling times (Tpot) in human colorectal cancers.

Authors:  M S Wilson; C M West; G D Wilson; S A Roberts; R D James; P F Schofield
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.